Evidence explainerMenopause & Perimenopause

HRT After 60: Starting vs Continuing, the Risks by Age, and What Changed in 2026

Starting hormone therapy after 60 and continuing it past 60 are different decisions. Guidelines see more risk in starting late, but no rule that says to stop at a set age, and vaginal estrogen can be used at any age.

By Kymata Labs EditorialPublished October 11, 2026Last verified October 11, 2026

Medical review pending. Written by our editorial team from the studies and documents cited below; a credentialed clinician has not reviewed it yet. Educational only, not medical advice.

Key takeaways

  • For women who start hormone therapy after age 60 or more than 10 years after menopause, the 2022 position statement says the benefit-risk ratio appears less favorable because of greater absolute risks of coronary heart disease, stroke, blood clots and dementia [1].
  • Continuing is different: hormone therapy does not need to be routinely stopped at 60 or 65 and can be continued past 65 for persistent hot flashes, quality of life or osteoporosis prevention after evaluation and counseling [2].
  • Vaginal estrogen, or other non-estrogen treatments, may be used at any age and for as long as needed for genitourinary symptoms [2].
  • In the WHI trials, excess adverse events per 10,000 women a year on estrogen plus progestin rose from 12 at ages 50 to 59 to 38 at ages 70 to 79 [3].
  • In February 2026 the FDA approved removing cardiovascular, breast cancer and probable dementia statements from the boxed warning on a first batch of six hormone therapy products [7].

Starting after 60 is not the same as continuing

Guidelines split the question in two. For healthy women under 60 or within 10 years of menopause, the 2022 position statement calls the benefit-risk ratio favorable for bothersome hot flashes and preventing bone loss. For women who start more than 10 years after menopause or after 60, it calls the ratio less favorable, citing greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia [1].

For women already on therapy, the statement's highlights say hormone therapy does not need to be routinely discontinued after 60 or 65, and that continuing past 65 can be considered for persistent hot flashes, quality-of-life issues or osteoporosis prevention after evaluation and counseling [2]. Longer use should be for a documented reason, with periodic reevaluation [1].

The numbers by age

The Women's Health Initiative (WHI) randomized 27,347 women aged 50 to 79 to conjugated estrogens with or without medroxyprogesterone acetate, or placebo [3]. Measured by a global index of serious events, the excess per 10,000 women a year on estrogen plus progestin was 12 cases at ages 50 to 59 and 38 at ages 70 to 79. On estrogen alone, women aged 50 to 59 had 19 fewer events while women aged 70 to 79 had 51 more [3].

Dementia is the age-specific worry. In the WHI Memory Study, which enrolled 4,532 women aged 65 or older, estrogen plus progestin roughly doubled the risk of probable dementia (hazard ratio 2.05), about 23 extra cases per 10,000 women a year [5].

Over 18 years of follow-up, neither WHI regimen changed overall death rates (27.1% with hormone therapy vs 27.6% with placebo) [4].

Route and dose matter more with age

The position statement's highlights say transdermal routes and lower doses may decrease the risk of blood clots and stroke [2].

A study of 10 million women on Medicare (2007 to 2020) linked estrogen alone continued past 65 with 19% lower mortality, and estrogen-plus-progestogen combinations with 10% to 19% more breast cancer; risk reductions were generally larger with low doses, vaginal or transdermal routes and estradiol rather than conjugated estrogens [6]. It is observational, so it shows associations, not cause and effect.

Note that WHI tested oral conjugated estrogens and medroxyprogesterone acetate [3]; the patches, gels and micronized progesterone common today were not what WHI studied.

What changed on the labels in 2026

On February 12, 2026, the FDA approved labeling changes for six menopausal hormone therapy products, removing statements on cardiovascular disease, breast cancer and probable dementia from the boxed warning; 29 companies had submitted proposed changes after the FDA started the process in November 2025 [7].

The FDA's announcement points to randomized evidence that women who start within 10 years of menopause, generally before 60, have lower all-cause mortality and fewer fractures [7]. That supports earlier starts; it is not evidence that starting at 65 or 70 carries the same balance. Our boxed-warning explainer has the details.

Vaginal estrogen and bone protection

For dryness, pain with sex and urinary symptoms (genitourinary syndrome of menopause), vaginal estrogen, systemic therapy if needed, or non-estrogen options may be used at any age and for extended duration [2]. Our page on vaginal estrogen online covers forms and access.

Hormone therapy has been shown to prevent bone loss and fracture [1], which is one reason the statement allows continuing past 65 for osteoporosis prevention after counseling [2].

Getting care after 60

Some online menopause services set an upper age limit; one we checked on Oct 11, 2026 prescribes hormone therapy only to women aged 35 to 59. If you are over 60, ask any service about eligibility before you pay, and bring your full history (clots, stroke, heart disease, breast cancer) to the visit.

Costs and providers are compared on our menopause treatment cost page and our menopause HRT online guide.

Partners we link to

  • GalaPaid linkOnline hormone care for women. Its hormone page (checked Oct 11, 2026) lists estradiol pill or patch, oral or vaginal progesterone, vaginal estradiol and non-hormonal options, and says blood or saliva hormone tests are usually not needed. Eligibility is decided at intake.See Gala's hormone plans (opens in new tab)

    Partner links may earn us a commission. Learn more

Quick answers

Is it too late to start HRT at 60?

Not automatically, but guidelines see a less favorable balance: for women who start after 60 or more than 10 years after menopause, the 2022 position statement cites greater absolute risks of heart disease, stroke, blood clots and dementia [1]. The decision depends on your symptoms and risk factors.

Should I stop HRT at 65?

Not routinely. The 2022 position statement says hormone therapy does not need to be stopped at 60 or 65 and can be continued past 65 for persistent hot flashes, quality of life or osteoporosis prevention after evaluation and counseling [2].

Does HRT after 60 raise dementia risk?

In the WHI Memory Study of women aged 65 or older, starting estrogen plus progestin raised the risk of probable dementia (hazard ratio 2.05, about 23 extra cases per 10,000 women a year) [5]. The FDA removed the probable dementia statement from the boxed warning on a first set of products in February 2026 [7].

Is vaginal estrogen safe after 60?

The 2022 position statement says vaginal estrogen, or non-estrogen options, may be used at any age and for extended duration for genitourinary symptoms [2].

Can HRT after 60 help osteoporosis?

Hormone therapy prevents bone loss and fracture [1], and continuing past 65 for osteoporosis prevention can be considered after counseling [2]. Starting it after 60 for bone alone is a risk-benefit decision to make with a clinician.

More in Menopause & Perimenopause

References

  1. [1]The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481
  2. [2]The North American Menopause Society releases its 2022 Hormone Therapy Position Statement (highlights). The North American Menopause Society, 2022.
  3. [3]Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 2013. PMID 24084921
  4. [4]Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 2017. PMID 28898378
  5. [5]Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. JAMA, 2003. PMID 12771112
  6. [6]Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause, 2024. PMID 38595196
  7. [7]FDA approves labeling changes to menopausal hormone therapy products. U.S. Food and Drug Administration, 2026.

Dietary supplements are not intended to diagnose, treat, cure or prevent any disease, and these statements have not been evaluated by the FDA. Prescription options need a licensed clinician. Talk to your clinician or pharmacist before starting anything new, especially if you take prescription medicines, are pregnant or breastfeeding.

Keep reading: Menopause and HRT

Menopause and HRT: every page →Women's hormone telehealth compared →Browse all topics →

Previous in this topicTestosterone for Women in Menopause: What It Treats, What It Doesn't, and How It's PrescribedTestosterone is popular on social media for energy, mood and weight after 40.Next in this topicWaking at 3 a.m. in perimenopause: what is happening and what helpsWhy women in perimenopause wake at 3 a.m.Red CloverRed clover is a meadow legume whose flower-top extracts, rich in isoflavones, are sold mainly for menopausal hot flashes.Midlife Strength: Creatine, Strength Training and Protein After 40, by the EvidenceCreatine added a little muscle and strength in postmenopausal women when paired with strength training, but it did not protect bone.Online Menopause HRT Compared (2026): 9 Providers, Real Monthly CostWomen's HRT providers compared on effective monthly cost, compounded vs FDA-approved forms, reviews and what's included, scored on a public rubric.

Menopause treatment cost →3 a.m. waking in menopause →